BioSpace News Archive

THINK Surgical, Inc., a leading innovator in the field of orthopedic robotic surgery, announced that Golden Valley Memorial Healthcare in Clinton, MO is among the first healthcare facilities to employ the second-generation TSolution One® robot for total knee arthroplasty.

Carisma Therapeutics announced today that Sanford (Sandy) Zweifach has been appointed to the chairman position for the Board of Directors.

Inhibikase today announced the publication of a paper describing the biochemical rationale and potential benefit of Abelson Tyrosine Kinase (c-Abl) inhibition as a potential disease-modifying therapy for Parkinson’s Disease.

EQRx to Present at the 4th Annual Evercore ISI HealthCONx Conference.

Ranok Therapeutics today announced an agreement with Pfizer Inc. to apply and evaluate Ranok’s CHAMP™ platform technology on an undisclosed cancer target.

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will host a hospital pipeline update for its novel antifungal, ibrexafungerp, during a webcast on Monday, December 6, at 10 a.m. ET.

Neurana Pharmaceuticals today announced it has completed enrollment of its 1,000 patient Phase 3 RESUME-1 Study of tolperisone for the relief of muscle spasm associated with acute, painful musculoskeletal conditions.

Carestream Health is showcasing cutting-edge medical imaging technology—designed to improve workflow, enable better diagnosis and enrich patient care—at the 2021 annual meeting of the Radiological Society of North America (RSNA).

SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., an innovative global pharmaceutical company focused on developing treatments for central nervous system (CNS) disorders, will present data on its anti-seizure medication (ASM) XCOPRI (cenobamate tablets) CV at the American Epilepsy Society (AES) Annual Meeting.

iX Biopharma Ltd, a specialty pharmaceutical company that develops innovative therapies using its proprietary sublingual drug delivery technology, WaferiX, announced that it has, through its subsidiary, entered into an exclusive license agreement with Seelos Therapeutics, Inc, a company focused on developing novel therapeutics for central nervous systems disorders.